Literature DB >> 16226682

Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids.

Jerzy-Roch Nofer1, Gerd Assmann.   

Abstract

Numerous epidemiological studies document an inverse relationship between plasma high-density lipoprotein (HDL) levels and the extent of atherosclerotic disease. The atheroprotective effects of HDL are more and more often seen in conjunction with the ability of HDL to restrict proinflammatory processes and thereby to carry out cytoprotection and organoprotection. Lysosphingolipids such as sphingosine 1 phosphate, sphingosylphosphorylcholine, and lysosulfatide are biologically active compounds that have recently been found to be associated with HDL particles. An increasing body of evidence suggests that several anti-inflammatory effects exerted by HDL can be attributed to the presence of lysosphingolipids in this lipoprotein fraction. In this review, we discuss the latest developments concerning the potential atheroprotective role of HDL-associated lysosphingolipids.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16226682     DOI: 10.1016/j.tcm.2005.08.005

Source DB:  PubMed          Journal:  Trends Cardiovasc Med        ISSN: 1050-1738            Impact factor:   6.677


  18 in total

1.  HDL and sphingosine-1-phosphate activate stat3 in prostate cancer DU145 cells via ERK1/2 and S1P receptors, and promote cell migration and invasion.

Authors:  Yoshitaka Sekine; Kazuhiro Suzuki; Alan T Remaley
Journal:  Prostate       Date:  2010-10-26       Impact factor: 4.104

2.  Sphingosine-1-phosphate receptor-2 deficiency leads to inhibition of macrophage proinflammatory activities and atherosclerosis in apoE-deficient mice.

Authors:  Fei Wang; Yasuo Okamoto; Isao Inoki; Kazuaki Yoshioka; Wa Du; Xun Qi; Noriko Takuwa; Koichi Gonda; Yasuhiko Yamamoto; Ryunosuke Ohkawa; Takumi Nishiuchi; Naotoshi Sugimoto; Yutaka Yatomi; Kunitoshi Mitsumori; Masahide Asano; Makoto Kinoshita; Yoh Takuwa
Journal:  J Clin Invest       Date:  2010-10-18       Impact factor: 14.808

Review 3.  Pharmacomodulation of high-density lipoprotein metabolism as a therapeutic intervention for atherosclerotic disease.

Authors:  Peter P Toth
Journal:  Curr Cardiol Rep       Date:  2010-11       Impact factor: 2.931

4.  Role of sphingosine 1-phosphate in anti-atherogenic actions of high-density lipoprotein.

Authors:  Koichi Sato; Fumikazu Okajima
Journal:  World J Biol Chem       Date:  2010-11-26

5.  High-density lipoprotein induces proliferation and migration of human prostate androgen-independent cancer cells by an ABCA1-dependent mechanism.

Authors:  Yoshitaka Sekine; Steve J Demosky; John A Stonik; Yosuke Furuya; Hidekazu Koike; Kazuhiro Suzuki; Alan T Remaley
Journal:  Mol Cancer Res       Date:  2010-07-29       Impact factor: 5.852

Review 6.  The role of HDL in plaque stabilization and regression: basic mechanisms and clinical implications.

Authors:  Jonathan E Feig; Jessica L Feig; George D Dangas
Journal:  Coron Artery Dis       Date:  2016-11       Impact factor: 1.439

7.  Loss of sex difference in high-density lipoprotein cholesterol in diabetic women during acute stress.

Authors:  Kristina Djekic; Eli Ipp
Journal:  J Clin Endocrinol Metab       Date:  2014-08-20       Impact factor: 5.958

8.  S1P in HDL promotes interaction between SR-BI and S1PR1 and activates S1PR1-mediated biological functions: calcium flux and S1PR1 internalization.

Authors:  Mi-Hye Lee; Kathryn M Appleton; Hesham M El-Shewy; Mary G Sorci-Thomas; Michael J Thomas; Maria F Lopes-Virella; Louis M Luttrell; Samar M Hammad; Richard L Klein
Journal:  J Lipid Res       Date:  2016-11-23       Impact factor: 5.922

Review 9.  Unraveling the complexities of the HDL lipidome.

Authors:  Anatol Kontush; Marie Lhomme; M John Chapman
Journal:  J Lipid Res       Date:  2013-03-30       Impact factor: 5.922

Review 10.  Signal transduction underlying the vascular effects of sphingosine 1-phosphate and sphingosylphosphorylcholine.

Authors:  Denise G Hemmings
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-04       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.